vorinostat has been researched along with Choriocarcinoma in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Choriocarcinoma: A malignant metastatic form of trophoblastic tumors. Unlike the HYDATIDIFORM MOLE, choriocarcinoma contains no CHORIONIC VILLI but rather sheets of undifferentiated cytotrophoblasts and syncytiotrophoblasts (TROPHOBLASTS). It is characterized by the large amounts of CHORIONIC GONADOTROPIN produced. Tissue origins can be determined by DNA analyses: placental (fetal) origin or non-placental origin (CHORIOCARCINOMA, NON-GESTATIONAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Muti-step screening identified vorinostat, camptothecin (S, +), topotecan, proscillaridin A, and digoxin as exhibiting an anti-cancer effect in choriocarcinoma cells." | 4.31 | Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma. ( Kajiyama, H; Kitagawa, M; Niimi, K; Nishino, K; Sugiyama, M; Watanabe, E; Yamamoto, E; Yamamoto, Y; Yokoi, A; Yoshida, K, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, E | 1 |
| Yokoi, A | 1 |
| Yoshida, K | 1 |
| Sugiyama, M | 1 |
| Kitagawa, M | 1 |
| Nishino, K | 1 |
| Yamamoto, E | 1 |
| Niimi, K | 1 |
| Yamamoto, Y | 1 |
| Kajiyama, H | 1 |
1 other study available for vorinostat and Choriocarcinoma
| Article | Year |
|---|---|
Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma.
Topics: Animals; Cell Line, Tumor; Choriocarcinoma; Female; Histone Deacetylase Inhibitors; Histone Deacetyl | 2023 |